Search
Sumario de resultados
TIpos de contenido
Fecha
-
AllyMontero Language Services
We are a company with 20 years of experience, offering a specialized translation service for Life Science industry among others. With the help of our multilingual team of more than 50 highly
-
-
OfferData Engineer
-
NewCash, cash equivalents and marketable securities totaled $22.7 million as of December 31, ...
Strong clinical progress in both oncology and CNS
-
-
-
-
-
Press release
AseBio showcases strategic capacity of Spanish biotechnology industry at Transfiere
The forum is held in Malaga with over 3,000 professionals from the science and innovation sector. AseBio is displaying innovative bioproducts from over a dozen member companies that are tackling the
-
NewAseBio showcases strategic capacity of Spanish biotechnology industry at Transfiere
The forum is held in Malaga with over 3,000 professionals from the science and innovation sector. AseBio is displaying innovative bioproducts from over a dozen member companies that are tackling the
-
NewTelum Therapeutics names Vincent A. Fischetti chairman of its Scientific Advisory Board
Professor Vincent A. Fischetti is the inventor of phage lysins as a new therapeutic and an alternative to conventional antibiotics
-
NewAsabys announces the first close of its fund, with commitments of €100M, and appoints Sylv...
Banco Sabadell stands as the firm’s main private institutional investor, like in its previous fund in 2018. Other Investors include the European Investment Fund and Alantra
-
-
EventSwiss Biotech Day 2023
-
Press release
#11F: AseBio launches first programme to pair female professionals and students in Spanish...
For International Day of Women and Girls in Science, 14 women from 12 companies will host young female students to encourage them to go into science and innovation and show them the different
-
-
-
New#11F: AseBio launches first programme to pair female professionals and students in Spanish...
For International Day of Women and Girls in Science, 14 women from 12 companies will host young female students to encourage them to go into science and innovation and show them the different
-
EventBioFIT 2023
-
NewaptaTargets’ ApTOLL reduces mortality from 18% to 5% in a Phase 1b/2a trial in ischemic st...
ApTOLL is the first TLR4 antagonist neuroprotectant to achieve positive efficacy endpoints in acute ischemic stroke trials, decreasing significantly mortality and long-term functional disability
-
NewORYZON to give updates on corporate progress in February-March
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today
